We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Bone-Disease Markers Monitor Response and Adherence to Osteoporosis Treatments

By LabMedica International staff writers
Posted on 04 May 2009
A range of automated bone-marker tests for the diagnostic and prognostic assessment of patients with or at risk of osteoporosis can be performed on a single serum work area platform. More...
The assays also provide an early indication of response and adherence to treatment.

The Elecsys range of bone marker, hormone, and bone mineral assays allows response to treatment and patient compliance to be monitored at an earlier stage (as early as three to six months after initiation of treatment) and throughout the course of treatment. This encourages adherence to treatment and provides medical staff with valuable information about its effectiveness. The traditional method for measuring response to treatment, bone mass densitometry (BMD), can take up to two years to demonstrate improvement to bone density

The comprehensive range of osteoporosis tests available from Roche Diagnostics (Burgess Hill, UK) for use with cobas or Modular Analytics serum work areas include the Elecsys bone-marker assays (ß-CrossLaps, total PINP [procollagen I N-terminal propertied], N-Mid Osteocalcin and vitamin D3-OH); the Elecsys hormone assays: parathormone, oestradiol, testosterone, dehydroepiandrosterone (DHEA) and sex hormone-binding globulin (SHBG); and bone mineral assays (calcium and phosphate).

According to the U.S. National Osteoporosis Society, one in two women and one in five men over the age of 50 will suffer a bone fracture, the main cause of which is osteoporosis. Among the most commonly used treatments for osteoporosis are the bisphosphonates. Although this group of drugs can be highly effective, gastric side effects and a complex treatment regimen can result in poor adherence. Alternative treatments, such as anabolic therapies, are more expensive, and therefore less likely to be prescribed as a first choice.

Roche is a world-leading healthcare company in the fields of diagnostics and pharmaceutics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis, and treatment of diseases. Roche is a developer of in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology.

Related Links:

Roche Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: TRUECAM automatically eliminates ambiguous or uninformative regions in whole-slide pathology images, enhancing the reliability of diagnostic analysis. (Photo courtesy of PolyU)

AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis

Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more

Industry

view channel
Image: HealthTab will distribute the Abbott Afinion 2 Analyzer to NHS-linked pharmacies for hemoglobin A1c (HbA1c) and lipid profile testing. (Photo courtesy of Abbott)

New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies

HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.